Response of 3-hydroxy-3-methylglutaryl CoA reductase to l-triiodothyronine in cultured fibroblasts from FH homozygotes

Atherosclerosis. 1995 Feb;113(1):91-8. doi: 10.1016/0021-9150(94)05431-h.

Abstract

The effect of l-triiodothyronine on 3-hydroxy-3-methylglutaryl CoA (HMG CoA) reductase activity was measured in cultured skin fibroblasts from patients with homozygous familial hypercholesterolemia (FH). The tested strains were obtained from 13 receptor-negative and 6 receptor-defective type homozygotes and 3 heterozygotes. Eleven out of 19 strains of cultured fibroblasts from FH homozygotes demonstrated high levels of the HMG CoA reductase activity when l-triiodothyronine was present in the culture medium. All the 11 strains that responded to l-triiodothyronine were the receptor-negative type in which the binding of LDL on the cell surface was completely lacking. Two receptor-negative type strains showed no response to the addition of l-triiodothyronine. In these strains, partially active receptors were synthesized and rapidly degraded. The effect of l-triiodothyronine on HMG CoA reductase was abolished by cycloheximide, and not by actinomycin D. Furthermore, the effect was abolished by the pre-loading of the cells with free cholesterol. The results indicate that the effect of l-triiodothyronine on HMG CoA reductase activity was a post-transcriptional event, required de novo protein synthesis, and was successful only when cholesterol was depleted from the cells. The difference in the responsiveness of HMG CoA reductase activity to l-triiodothyronine treatment can be utilized to judge the state of impairment of LDL-receptors in the FH homozygote from the viewpoint of ability to incorporate cholesterol into the cells.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Cells, Cultured
  • Cycloheximide / pharmacology
  • Dactinomycin / pharmacology
  • Fibroblasts / cytology
  • Fibroblasts / drug effects
  • Fibroblasts / enzymology
  • Homozygote
  • Humans
  • Hydroxymethylglutaryl CoA Reductases / metabolism*
  • Hyperlipoproteinemia Type II / enzymology*
  • Hyperlipoproteinemia Type II / genetics
  • Hyperlipoproteinemia Type II / metabolism
  • Lipoproteins, LDL / metabolism
  • Receptors, LDL / deficiency
  • Receptors, LDL / metabolism
  • Skin / cytology
  • Triiodothyronine / pharmacology*

Substances

  • Lipoproteins, LDL
  • Receptors, LDL
  • Triiodothyronine
  • Dactinomycin
  • Cycloheximide
  • Hydroxymethylglutaryl CoA Reductases